Posted by Michael David on June 8, 2013
Michael A. Caligiuri, M.D.
300 W. 10th Ave., Suite 519
Columbus, Ohio 43210
Tel: (614) 293-7521
Fax: (614) 293-3132
Information on The Ohio State University Comprehensive Cancer Center (OSUCCC)
The James is a cutting-edge research facility where discovery is translated into more effective prevention and diagnostic strategies as well as more effective and safer treatments. Among recent research advances:
- The James was one of many sites in a national study involving 18,000 men that demonstrated the ability of a hormonal agent, finasteride, to reduce the risk of prostate cancer by 25 percent. More than 250 men in Ohio and Kentucky participated through the Ohio State clinics directed by Steven K. Clinton, MD, PhD, and Robert Bahnson, MD. The study was the first in history to demonstrate that an intervention could protect men from developing prostate cancer.
- The James is participating in the largest prostate cancer prevention trial to date, called SELECT (Selenium and Vitamin E Cancer Prevention Trial). The Ohio State effort, directed by J. Paul Monk, MD, and Drs. Clinton and Bahnson, will determine whether dietary supplements of vitamin E and selenium can prevent prostate cancer. The 12-year study is expected to involve more than 400 trial sites, with approximately 32,000 healthy men over the age of 55 (over 50 for African-Americans) participating.
- Dr. Clinton and colleagues at the OSUCCC – James are seeking to prove whether consumption of tomato-based products and soy can reduce the risk of prostate cancer, as epidemiologic studies have suggested. These investigators are bringing dietary and nutritional studies into the clinic, where men with prostate cancer are able to participate in these important and exciting clinical trials
Under the leadership of Dr. Michael A. Caligiuri, the Ohio State University Comprehensive Cancer Center (OSUCCC) is the umbrella organization over all aspects of cancer care, research and education at the University. Designated as a comprehensive cancer center by the National Cancer Institute in 1976, the OSUCCC brings together more than 220 faculty investigators representing 14 colleges at The Ohio State University (OSU) as well as at our affiliated institutions that include the Columbus Children’s Hospital and the Cincinnati Children’s Hospital Medical Center.
The OSUCCC membership is organized as a network of seven interdisciplinary, cancer-focused research programs with seventeen state-of-the-art shared resource facilities and a robust administrative infrastructure. Because of our focus in translational research coupled with an active NCI-funded Phase I program, the OSUCCC has extensive expertise in conducting early phase clinical trials. In addition, the OSUCCC continues to be a leader in the NCI cooperative group networks as demonstrated by our being a main institution, correlative science center, tissue repository and now the central imaging core for CALGB. Finally, as Ohio is home to several large and distinct populations, including Amish and rural Appalachia, the OSUCCC has been successful in pursuing unique cancer genetics and population-based research programs within these communities, including an NCI-funded Center for Health Disparities in rural Appalachia. These demonstrated strengths have led the OSUCCC leadership to target three research areas of excellence for significant recruitment and expansion in the future: Human/Clinical Cancer Genetics, Experimental Therapeutics and Cancer Prevention/Control.
The focal point of the clinical activities of the OSUCCC are located in the Arthur G. James Cancer Hospital (OSU-James), a free standing, 160 bed state-of-the art facility for adult cancer clinical inpatient and outpatient activities and clinical laboratory support services. In addition, the OSU James functions as the central hub for supporting several other cancer clinical care facilities and affiliated sites located regionally in Ohio. Built in 1990, the OSU-James also houses the Cancer Clinical Trials Unit that provides specialized support and staffing for early phase investigational drug delivery. Coupling our strengths in translational research, cancer genetics and prevention/control with the unique nature of the OSU-James, the OSUCCC is now at the forefront of developing individualized therapeutic approaches to cancer care and treatment.
In 2003, with the commitment of the University, the OSUCCC began formal planning for a dramatic expansion of the clinical and research facilities. Estimated at more than $600M, this expansion will increase the number of dedicated cancer inpatient beds to nearly 300 with a 10-fold increase in outpatient space and more than 150,000 square feet of dry/wet laboratory, shared resource and office space. Nearly 100,000 square feet of the research space will be ready for occupancy in Fall 2006 with construction of the clinical facilities beginning in 2007.